The stock market is no place for fairness where the insiders are concerned.
They will do anything to turn a profit. But we can use their greed in order to earn big money ourselves!
And this current situation unfolding right now could be one of those chances to earn huge profits quickly…
Why are company insiders in the stock market? Why don’t they just stick to their day jobs?
It’s simple…they want to make money, and they have the best chance of doing so!
Any insider, even the biggest insiders who reside in Congress, could gain privileged information about their company at any moment. And if that information points towards the price of the stock going up, they suddenly have a fast pass to big money.
For the sole reason of priority access to the type of news that could truly impact the price of a stock, the insiders are always a threat to profit.
So why not follow them to those profits?
Where the insiders make a killing…
Insiders do a ton of damage within the technology and healthcare sectors. Think about it…tech companies can spring a new piece of technology on us at any moment, and pharmaceutical companies have the potential to create a brand new vaccine at anytime.
That makes both of those areas very important where big-time profit opportunities are concerned.
That’s why I’m very interested in Atara Biotherapeutics, Inc. (ATRA).
This biopharmaceutical company focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology, and the company insiders aren’t shy when it comes to buying shares…
This recent IPO, initial public offering, just experienced insider purchases by 4 insiders of approximately 420,000 shares totaling a value of more than $3.3 million!
That is some real excitement out of the insiders, and it could be a big hint to profits for us…
And here’s why I like this stock even more…
ATRA just announced the dosing of the first patient in its Phase 1 clinical study of STM 434, which is an active inhibitor in patients with ovarian cancer and other diseases.
That news mixed with the insider buying tells me that the insiders may already know how well this new inhibitor will perform.
This biopharma stock appears to have plenty of appealing qualities, but it’s also in the early stages of its life, which can be the most volatile.
Now it’s all about timing. If we enter the trade too early, we could be stopped out almost immediately. But if we time it right, we could be on the verge of big profits.
To know WHEN to enter the trade, get the secrets taught in our Stock Code Breaker course.
